-
Search Underway for 'Dooars Rani' Tigress After Second Escape from Buxa Tiger Reserve
-
Teatro Mayor Unveils 152-Performance 2027 Season Highlighting Beethoven and García Márquez
-
The Dilemma of Recording Live Music: Preserving Memories vs. Being Present
-
Rutgers Defeats NJIT 101-64 Behind Francis and Mark Scores
-
AmeriLife Welcomes Finance Veteran Richard Dziadzio as Chief Financial Officer; Names Jim Quinn President & Chief Transformation Officer
-
6 Pieces of Furniture Worth Investing In
-
Fulcrum Metals PLC Announces New Critical Mineral Recoveries Expand Potential
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 11
-
Guardian Metal Resources PLC Announces Proposed Spin-Out of Non-Tungsten Projects
-
Fulcrum Metals PLC Announces Publication of Updated Investor Presentation
-
THIEAUDIO Introduces Clairvoyance MKII: The Evolution of a Signature Sound
-
Christmas Day Shifts More than Double as Americans Return to In-Person Holiday Celebrations
-
BlackBerry to Participate in Upcoming Investor Conferences
-
NiobiumX Mining Reports Results of Ground Radiometric Survey at Shipshaw, Maps Two Distinct Radiometric Signatures Across the Core Claims, and Moves to a High-Resolution Airborne Survey of the Full 2,686-Hectare Package
-
Irving Resources Reports on Drilling in Yamagano Mining Right at the Yamagano Joint Venture, Kyushu, Japan
-
Trifecta Gold Reports 2026 Exploration Results from the Liam and Lois Projects, Tombstone Gold Belt, Yukon
-
XCF Global Hosts USDA at New Rise Renewables Reno as Facility Surpasses 4.4 Million Gallons Since Restart
-
5E Advanced Materials to Host Fiscal First Quarter 2027 Earnings Conference Call on November 17, 2026
-
Patriot Software Adds Performance Reviews to Patriot HR
-
Protagenic Therapeutics Announces Private Placement of Up to $5 Million to Advance PT00114 into Its First U.S. Clinical Trial in Generalized Anxiety Disorder
-
Healixa's FrostPulse(TM) Technology Solves a Major Roadblock to Data Center Growth: Cooling Without the Water Burden
-
Route1 Announces 2026 Annual Meeting Results
-
NuRAN Wireless Board Approves Growth Strategy to Scale Recurring Revenue from 5,000+ Contracted Towers
-
Ethur Takes On Hiring Fraud With Facial Biometrics Identity Checks and Connected Payroll and Bank Data
-
PPX Mining Reports Callanquitas Operating Results for the First Nine Months of 2026
-
Green Leaf Innovations (OTC: GRLF) Meets OTCID Disclosure Requirements Following Profitable Q2 2026 Results
-
Valion Bio Reinforces Commitment to American Troops; Discusses Entolimod with Attendees at RW Baird's National Security Conference
-
Amarc Extends 2026 Exploration Program at the Duke District: Initiates Drilling Program at Established Porphyry Copper-Gold Targets
-
Thukukile Zuma Resigns from ANC Johannesburg Leadership Amid Disciplinary Dispute
-
Russia Orders 100,000 Kometa Modules to Counter Ukrainian Electronic Warfare
-
CM Mohan Yadav Meets Bohra Spiritual Leader to Discuss Simhastha 2028 and Development
-
Mahayuti-backed Rajesh Patil Elected Chairman of Gokul Dairy Amidst Political Deadlock
-
Eli Crane Defeats Jonathan Nez in Tight Arizona Congressional Race
The technology fighting Rwanda's silent killer of women
When Rwandan villager Lillian was diagnosed with cervical cancer, the 30-year-old feared that her life was over. But a new gadget aimed at patients in low-income countries offered her hope.
"The medical diagnosis was very scary; my husband couldn't believe it," Lillian -- not her real name -- told AFP.
"We had heard of people dying of cancer and that it was incurable, so it was a very scary moment."
Her fears were not unfounded.
Cervical cancer is a notorious "silent killer" of women, but especially so in poor countries that lack affordable treatment and diagnostics.
In Rwanda, it is the most commonly diagnosed cancer, attacking 42 out of every 100,000 women, three times the global average, according to national statistics.
The stigma and fear surrounding the disease and its connection to HIV -- a major risk factor for cervical cancer -- means many Rwandan women are reluctant even to get tested.
And those who are diagnosed often assume that treatment is out of bounds, unless they live in a major city.
For Lillian, whose village is a three-hour drive east of the capital Kigali, the likelihood of emerging cancer-free, less than four months after diagnosis, seemed like a fantasy.
But in 2020, Rwanda decided to trial a portable device that treats precancerous lesions with heat and can be used in countries with limited access to advanced equipment or facilities.
"The nurse who treated me used a small gadget that looked like a gun. It is uncomfortable but not painful, even when it uses heat to kill the cancer lesions," Lillian said.
- Energy-efficient solution -
The so-called C3 thermocoagulator is a pistol-like probe that uses battery power, meaning it can be deployed in remote areas without 24/7 access to electricity.
"The device works by applying heat to the cervix, which causes the abnormal cells to die," Christine Musabyeyezu, a nurse at Kigali's Remera health centre, told AFP.
Aimed at being a cost-effective alternative to cryotherapy, the traditional technology used in the treatment of cervical cancer, the device is simple to use, requiring minimal training for health workers, she said.
"At first we relied on cryotherapy to treat cervical cancer lesions, but this method is complicated, expensive and not easily accessible across the country," Musabyeyezu said.
Cryotherapy, which applies a probe to the cervix to freeze lesions, utilises a lot of energy to ensure that the probe is cold enough.
The thermal devices on the other hand are energy-efficient, offering a week's worth of use (around 140 treatments) before requiring a recharge.
The gadgets are now at the epicentre of Rwanda's fight against cervical cancer, particularly in rural areas.
The Central African nation is among seven sub-Saharan countries that have adopted the device, made by a German company, WISAP Medical Technology.
- 'Test early, treat early' -
Health workers in Rwanda are also hopeful that the success of C3 will go hand-in-hand with a potential breakthrough in diagnostics.
Highly diluted acetic acid -- vinegar -- has become an established method for spotting pre-cancerous lesions on the cervix, which turn white in the presence of the substance.
However, human interpretation of the test can vary, which is where a mobile app powered by artificial intelligence comes in, boosting accuracy as well as speed.
According to Marisol Touraine, president of the international health agency Unitaid, which is supporting medical trials of the app in Rwanda, more than 300,000 women lose their lives to cervical cancer every year.
The vast majority of these deaths -- a staggering 90% -- occur in low-income countries "because they were not screened in time, because they were not treated in time," Touraine told AFP.
The increase in the number of women coming forward to get tested in Rwanda is good news, said nurse Musabyeyezu.
"There is always a queue here of women coming to test for cervical cancer, more than for any other medical tests," she said.
"This is a good thing because when they test early they can be treated early."
F.Dubois--AMWN